CONFERENCE DAY ONE
FEBRUARY 18, 2025
PART ONE: FIND YOUR FUTURE PARTNER
Bringing you a targeted and scientifically aligned partnership opportunity from the start, this opening section brings key buyers
together in a unique and unmissable format to find your next partner and route to more capital.
9:00 - 9:45: Investor Panel: Hear differences across investor strategies when evaluating different stages of company and asset development
9:45 - 10:30: Investor Icebreaker: Join six high tables with an investor at each for a speed networking style icebreaker. Catch the investors and swap business cards where there is alignment between wants and needs
12:45 - 1.15: Pharma Panel: Understand what’s in-scope or out of strategy for pharma business development looking to expand portfolios across cardiometabolic and renal indications
1:15 - 2:15: Pharma Icebreaker: Take part in face-to-face matchmaking for protected networking with pharma business leads. Hear invaluable feedback and qualify yourself as a company of interest
8:00-8:30 am One-on-One Partnering Scheduling Block One. One-on-One PartneringTM platform meeting schedule starts. Grab a coffee & sit down with key contacts in the hour before the conference at bookable meeting spaces
8:50 am Chair’s Opening Remarks
Strategic Priorities & Deal Trends: Reviewing Gaps in the Cardio-Renal-Metabolic Arena to Fuel First- & Best-in-Class Programs
9:00 am Investor Panel: What Data Package is Exciting Enough to Invest in?
Synopsis
- What makes novel targets an exciting area for investment? What is each fund excited about going forward in terms of data or company type?
- What does the panel see as newer and more interesting differentiation points?
- Considering the duration of clinical trials within the cardio-renal arena, what data is needed to get a committed buyer on board?
9:45 am Investor Icebreaker Networking: Ensure you Connect
Synopsis
Jump into a speed networking style session to efficiently gauge alignment between investors and your stage of company or asset. Comment on their perspectives from the panel and swap business cards for follow up outside the conference.
Six high tables with an investor at each, introduce your company six times with 7 minutes per round.
10:30 am Morning Break & Networking
11:00 am Pharma Panel: Activity & Ambition for Deal-Making to Improve the Standard of Care
Synopsis
- Understanding and appreciating why pharma would invest: What gap are the innovative therapies filling and how are they differentiated to improve the current standard of care?
- Which biologies invite interest and is there appetite to return to historical targets: How does this play through into prioritizing disease areas and co-morbidities of interest?
- How to drive appetite for platform investment?
- How much is the patient preference for chronic disease management a priority: How does this translate into innovation?
11:30 am Pharma Icebreaker Networking: Ensure you Connect
Synopsis
For interested parties to guarantee meeting time with each other, both pharma and attending biotech can select companies of interest for pre-organized sit-down meetings.
Guaranteeing value by securing face-to-face meetings with priority companies, benefit from introducing yourself, or catching pharma you’ve not scheduled meetings with through the One-on-One PartneringTM portal early in the event.
12:45 Lunch & Networking
1:00-2:00 pm One-on-One Partnering Scheduling Block Two
PART TWO: SCIENTIFIC SHOWCASE
Designed to foster excitement and engagement in innovative companies, be part of back-to-back presentations to validate your
technology as solving scientific hurdles and differentiated versus peers to a group of aligned and qualified decision-makers.
Bolstering Safety & Efficacy With Next-Generation Mono- & Combination Therapies to Improve the Standard-of-Care
2:15 pm Insight From Hibernation: Discovery of a New Treatment Modality for HFpEF/PH Based on Natural Cardioprotection Mechanisms
Synopsis
- Hibernating ground squirrels are able to reverse cardiac damage that occurs during the hibernation cycle
- Linking these mechanisms to human disease datasets led to a novel treatment strategy for HFpEF/PH patients
- Faun1083 has compelling in-vivo efficacy and is currently entering IND-enabling studies with a goal of entering the clinic in early 2026
2:45 pm Achieving Quality Weight Control with Selective Biologics Targeting ActRIIA for Sustainable Obesity Management
Synopsis
- Achieving muscle preserving weight management
- Demonstrating ActRII signaling in regulating muscle and fat mass, and bone density
- Development of ActRII antibody LAE102 for quality weight loss
3:15-4:30 pm One-on-One Partnering Scheduling Block Thre
4:40 Drinks Reception:
Enjoy an informal networking drinks reception with all attending and presenting companies to catch up with key stakeholders outside of the regular meeting, as a touchpoint, specific for this community, ahead of BIO.